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Abstract  
Background: Relative dose intensity (RDI) is an indicator of therapeutic efficacy in 
sunitinib (SU) treatment for metastatic renal cell carcinoma (mRCC). However, the 
number of studies investigating the influence of decreased RDI during the early phase on 
oncological outcome is limited.   
Methods: A total of 105 patients who received first-line SU treatment for mRCC were 
evaluated. We assessed the RDI during the initial first cycle (1c-RDI). We found that an 
optimal threshold of 1c-RDI was associated with progression-free survival (PFS) and 
overall survival (OS) after the initiation of SU treatment. Additionally, predictive factors 
for decreased 1c-RDI were analyzed.  
Results: The 1c-RDI threshold was determined at 60%. Patients with low 1c-RDI (< 60%, 
n = 26, [24.8%]) had significantly shorter median PFS (5.79 vs. 14.0 months, p = 0.0014) 
and OS (13.3 vs. 34.4 months, p = 0.0005) durations than those with high 1c-RDI (≥ 60%, 
n = 79 [75.2%]). Multivariate analysis showed that the development of dose-limiting 
toxicity was an independent factor for low 1c-RDI (odds ratio: 3.09, 95% confidence 
interval: 1.14 – 8.37, p = 0.0266) after adjustment with an initial dose of SU.  
Conclusions: More than 60% of 1c-RDI is needed for effective SU treatment. Patient 
tolerability should be carefully monitored to avoid the development of dose-limiting 
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toxicity during the early phase of treatment. 
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Mini Abstract 
More than 60% of 1c-RDI is needed for effective sunitinib treatment. Patient tolerability 
should be carefully monitored to avoid the development of dose-limiting toxicity during 
the early phase of treatment. 
  
Dose intensity in sunitinib for mRCC   Ishihara et al. 
7 
 
Introduction 
Sunitinib (SU) is an anti-cancer drug and a receptor tyrosine kinase inhibitor mainly 
targeting the vascular endothelial cell growth factor receptors and blocks vascular 
endothelial cell growth factor signaling. It is approved as a first-line molecular-targeted 
agent for metastatic renal cell carcinoma (mRCC) [1]. SU is more beneficial to patient 
survival than conventional cytokine therapy [2,3], and has been broadly applied in current 
clinical practice. However, its toxicity is a major issue. Frequent and severe adverse 
events (AEs) induced by SU can result in treatment withdrawal, dose reduction, or 
treatment interruption, that is, dose-limiting toxicity (DLT) [2,4-9].  
In a previous pivotal trial, SU-induced toxicities, mainly gastrointestinal disorder, 
hypertension, hand-foot syndrome, general fatigue, or hemototoxicity, led to dose 
reduction and treatment termination in 50% and 19% of the patients, respectively [2]. 
DLTs can directly decrease relative dose intensity (RDI). Maintaining the RDI, 
particularly in the early phase of treatment, is essential to efficient and continuous 
treatment, and is significantly associated with patient survival [10,11]. However, the 
number of studies investigating the impact of decreased RDI during the early phase of 
treatment on the oncological outcome is limited, particularly in patients without prior 
cytokine therapy. Moreover, predicting the decreased RDI before initiation of treatment 
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or during treatment is difficult. Thus, risk factors for such a possibility should be 
identified.  
In this study, we investigated the influence of decreased RDI during the early phase 
on the therapeutic efficacy of first-line SU treatment in patients with mRCC without prior 
cytokine therapy. Additionally, risk factors for decreased RDI were analyzed.     
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Materials and Methods 
Study design 
First of all, we nominated patients who received at least one dose of oral SU. In our 
department between January 2007 and July 2017, 112 patients received first-line SU 
treatment for mRCC without prior cytokine therapy. Of these, we excluded those who had 
either undergone a kidney transplantation (n = 1) or whose clinical data was lacking (n = 
6). Finally, 105 patients were evaluated in this retrospective single-center analysis. All 
study procedures were approved by the Institutional Review Board of Tokyo Women’s 
Medical University, and were in accordance with the Declaration of Helsinki (ID: 4551). 
To determine the influence of decreased RDI during the early phase of treatment 
on the therapeutic efficacy of first-line SU for mRCC, we calculated the RDI during the 
initial first cycle (1c-RDI) as RDI in early phase. Patients were classified into the 
following two groups, low and high 1c-RDI, based on the 1c-RDI threshold associated 
with oncological outcome, including progression-free survival (PFS) and overall survival 
(OS), after initiation of treatment. Furthermore, we analyzed the predictive factors for 
decreased 1c-RDI.  
 
Protocols of first-line sunitinib treatment  
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We followed the protocol for first-line SU treatment as described elsewhere [12,13]. 
Briefly, the main agent for first-line molecular-targeted therapy was SU. Patients with 
mRCC were treated using a 4-week-on/2-week-off or a 2-week-on/1-week-off schedule. 
SU treatment was initiated at a dosage of 50 mg/day and was modified based on individual 
patient factors. Three factors were considered for the reduction of the initial dose: (1) age: 
> 65 years, (2) serum creatinine levels: > 2 mg/dL, and (3) a body weight: < 50 kg. If one 
of these three factors was observed, the initial dose was reduced to 37.5 mg. If two factors 
were observed, the initial dose was reduced to 25 mg. We never reduced the initial dose 
to < 25 mg. The dose was subsequently increased by 12.5 mg until the highest tolerable 
dose was determined, although the dose never exceeded 50 mg. Toxicity was assessed at 
each visit (every 1–2 weeks during the first cycle) and then every month according to the 
patient’s condition. AEs were graded using the Common Terminology Criteria for 
Adverse Events of the National Cancer Institute, version 4.0. The dose was reduced or 
interrupted based on the guidelines for SU therapy.  
 
Statistical analysis 
Continuous and categorical variables were analyzed using the Mann-Whitney U-
test and the χ2 test or Fischer’s extract test, respectively. PFS and OS were defined as the 
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time from therapy initiation to the date of progression and date of death from any cause, 
respectively. Survival was calculated using the Kaplan-Meier method and compared 
using the log-rank test. Univariate and multivariate logistic regression analyses were used 
to identify risk factors for low 1c-RDI. Also, univariate and multivariate analyses using 
Cox proportional hazards regression models were used to identify the prognostic factors 
for PFS and OS. The risk was expressed as odds ratios (ORs) or hazard ratios (HRs) with 
95% confidence intervals (CIs). All analyses were performed using JMP software 
(version 13; SAS Institute Inc., Cary, NC, USA), and p-values < 0.05 were considered 
statistically significant.  
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Results  
Patient background 
We examined a threshold of 1c-RDI influencing PFS and OS. Consequently, a 1c-
RDI threshold of 60% was determined to be strongly associated with PFS and OS after 
evaluating the p values of various thresholds of 1c-RDI and selecting the threshold with 
the lowest p values (Table 1). Based on the threshold, 26 patients (24.8%) were classified 
into the low 1c-RDI group (i.e., < 60%). Female sex (p = 0.0053), low initial dose of SU 
(p = 0.0345), and higher incidence of DLT were more frequently observed in the low 1c-
RDI group than in the high 1c-RDI group. Other clinicopathological factors, including 
age, body weight, pathological type, prior nephrectomy status, the Memorial Sloan 
Kettering Cancer Center risk classification, number of metastatic sites, or treatment 
schedule did not significantly differ between the two groups (all p > 0.05) (Table 2). The 
follow-up period was significantly shorter in patients with low 1c-RDI than those with 
high 1c-RDI (p = 0.0037). 
 
Survival according to 1c-RDI 
In the follow-up period, 73 patients (69.5%) experienced disease progression, and 
59 patients (56.2%) died of any cause. Figure 1 shows that the median duration of PFS 
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and OS were significantly shorter in patients with low 1c-RDI than those with high 1c-
RDI (PFS: 5.79 [95% CI: 2.76 – 8.02] vs. 14.0 [95% CI: 10.7 – 20.7] months, p = 0.0014; 
OS: 13.3 [95% CI: 4.73 – 20.0] vs. 34.4 [95% CI: 26.1 – 52.6] months, p = 0.0005).  
 
Predictors for low 1c-RDI  
Table 3 shows the results of univariate and multivariate logistic regression analyses 
for 1c-RDI < 60%. Univariate analysis showed that female sex, lower initial dose, and 
DLT development were associated with low 1c-RDI (all, p < 0.05). Multivariate analysis 
showed that DLT development (OR: 3.09, 95% CI: 1.14 – 8.37, p = 0.0266) and female 
sex (OR: 3.11, 95% CI: 1.16 – 8.34, p = 0.0240) were independent predictors for low 1c-
RDI after adjustment for the initial dose of SU.    
 
Predictors for progression-free survival and overall survival 
   Supplementary Tables 1 and 2 show the results of univariate and multivariate analyses 
for PFS and OS, respectively. Multivariate analysis shows that 1c-RDI was an 
independent predictor (HR: 2.23, 95% CI: 1.27 – 3.79, p = 0.0063), along with sex (HR: 
1.74, 95% CI: 1.02 – 2.90, p = 0.0415), histology (HR: 1.97, 95% CI: 1.15 – 3.31, p = 
0.0135), MSKCC risk (p = 0.0154), and the number of metastatic sites (HR: 1.77, 95% 
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CI: 1.10 – 2.88, p = 0.0195) for PFS. For OS, 1c-RDI was an independent predictor (HR: 
2.64, 95% CI: 1.45 – 4.68, p = 0.0018), along with histology (HR: 2.07, 95% CI: 1.13 – 
3.70, p = 0.0199), MSKCC risk (p = 0.0026), and the number of metastatic sites (HR: 
2.65, 95% CI: 1.53 – 4.68, p = 0.0195), according to the multivariate analysis.  
 
Dose-limiting toxicities during the initial first cycle  
Table 4 shows the individual AEs that cause DLTs. The most frequent AE was 
thrombocytopenia (grade 2: n = 16 [30.8%], grade ≥ 3: n = 14 [26.9%]), followed by 
leukocytopenia (grade 2: n = 3 [5.77%], grade ≥ 3: n = 11 [21.2%]). Among the 52 patients 
who developed DLT, the dose was reduced and interrupted in 31 (59.6%) and 21 (40.4%) 
patients, respectively.    
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Discussion 
     The present study indicated that more than 60% of RDI during the initial first cycle 
was needed to maintain the therapeutic efficacy of first-line SU treatment for mRCC. 
Furthermore, we found that DLT development can decrease the level of sufficient RDI; 
therefore, patient tolerability should be carefully monitored to avoid the development of 
DLT during the first cycle. 
SU-induced toxicities can disrupt the maintenance of efficient treatment intensity, 
and this can result in poor prognosis in patients with mRCC. Kawashima et al. reported 
that continuing treatment for more than one course and ≥ 60% of one-month RDI were 
important for optimal efficacy of SU treatment [11]. Another study reported that dose 
intensity below 70% during several landmark periods, including the initial three cycles, 
was significantly associated with shorter OS in SU treatment [10]. Considering these 
findings, a threshold of 60% obtained from our analysis was consistent with the findings 
from previous studies. Notably, a unique point of the present study was that it included 
patients who had not received prior cytokine therapy. Thus, our findings can be applied 
on the current treatment strategy for mRCC [14].  
As RDI is affected by various factors during treatment, predicting it before 
treatment initiation or during treatment is difficult. Moreover, despite the need for 
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predictors for decreased RDI that can be used to prevent it during treatment, only a limited 
number of clinical researches have focused on such factors. As such, we found that the 
development of DLT during the initial first cycle should be avoided to maintain the 
efficient RDI. As the initial dose of SU would be directly associated with 1c-RDI, 
multivariate analyses were performed to adjust for the confounding factors. The results 
indicated that DLT development remains a statistical significant factor influencing the 
RDI.  
Treatment discontinuation induced by intolerable AEs was previously reported to 
negatively affect patient prognosis [10,15]. Treatment was permanently discontinued 
after interruption during the early phase in eight of the 31 patients (25.8%) in our study. 
In these eight patients, the median 1c-RDI was 46.5%, and the survival was extremely 
poor (median PFS and OS: 1.16 and 3.35 months, respectively). Also, in this study, total 
RDI (i.e., throughout the treatment) in patients with low 1c-RDI was lower than in those 
with high 1c-RDI (median: 45.6% vs. 64.2%, p < 0.0001), suggesting that deterioration 
of therapeutic efficacy in early period influences entire efficacy, leading to poor survival.  
In the current analysis, the most frequent DLTs were hematotoxicities, including 
thrombocytopenia and leukocytopenia, that could not be treated or prevented via 
symptomatic treatment. A similar finding was observed in a previous study by 
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Kawashima et al. who reported that thrombocytopenia and leukocytopenia were the most 
frequent AEs in SU treatment [11]. Furthermore, a modified treatment schedule was not 
associated with a maintenance of efficient RDI, although a 2-weeks-on/1-week-off 
schedule is a common alternative schedule with less toxicity [16-18]. However, the 
deceased drug efficacy during the early phase of treatment can negate the benefit from 
the modified schedule. Thus, when severe hematotoxicities occur during the initial cycle, 
a conversion to other agents, such as pazopanib, which is more tolerable than SU with 
less hematotoxicity effects [4,5], may be a more effective approach than reduced dosage 
or schedule modification. The lower frequency of thrombocytopenia and leukocytopenia 
in pazopanib than that of SU has been demonstrated [4]. 
Finally, our analysis showed that female patients had a higher risk of decreased 
RDI than males. This finding was similarly observed in several previous studies. 
Kawashima et al. reported that women tended to discontinue SU treatment within one 
course [11]. In their review of SU treatment, Segarra et al. reported that female patients 
had a higher incidence of AEs than males [19]. Kaymakcalan et al. suggested that further 
researches should be performed to determine the impact of sex on SU-induced toxicity 
[20].   
This study had several limitations. First, this study was retrospectively performed 
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in a single-center with a relatively small cohort. Our findings were affected by 
unavoidable biases in patient or treatment selection. Moreover, several unrecorded AEs 
might exist. Second, we should note that the safety profile of SU may differ between the 
Asian and Western populations [21]. Third, an initial dose of SU was modified using a 
home-based protocol (based on age, body weight, and renal function) according to 
previous studies showing a high concentration of SU and its active metabolite in plasma 
with a dosage of 50 mg [22], and higher incidence of AEs in Japanese than Western 
patients [23]. Indeed, some studies reported the possibility of weak tolerability in elderly 
patients [24,25]. Moreover, SU can deteriorate renal function [26,27]. In this context, our 
own protocol can reflect the situation in real world, but we should recognize some 
possible bias in the protocol.   
In conclusion, more than 60% of 1c-RDI was needed to maintain the therapeutic 
efficacy of first-line SU treatment for mRCC. The development of DLT during the initial 
first cycle can deteriorate the 1c-RDI regardless of the initial dose or treatment schedule 
of SU. Patient tolerability should be monitored carefully during the early phase of 
treatment.     
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Figure legends 
Figure 1. Progression-free survival and overall survival according to 1c-RDI 
threshold 
Median progression-free survival and overall survival were significantly shorter in 
patients with low 1c-RDI (progression-free survival: 5.79 vs. 14.0 months, p = 0.0014; 
overall survival: 13.3 vs. 34.4 months, p = 0.0005).  
1c-RDI, relative dose intensity during the initial first cycle 
Figure 1
1cRDI < 60%  13.3 months (95% CI: 4.73 – 20.0)
1cRDI ≥ 60% 34.4 months (95% CI: 26.1 – 52.6)
p = 0.0005
1cRDI < 60%  5.79 months (95% CI: 2.76 – 8.02)
1cRDI ≥ 60%  14.0 months (95% CI: 10.7 – 20.7)
p = 0.0014
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Table 1: Determination of the cult-off value of 1c-RDI associated with survival  
 n PFS OS 
Cut-off value of 1c-RDI ≥ vs. < HR 95% CI p HR 95% CI p 
55 82 vs. 23 1.95 1.09 – 3.31 0.0256 2.21 1.22 – 3.83 0.0061 
60 79 vs. 26 2.31 1.33 – 3.84 0.0035 2.55 1.45 – 4.36 0.0015 
65 67 vs. 38 1.59 0.97 – 2.55 0.0664 1.88 1.11 – 3.15 0.0185 
70 59 vs. 46 1.58 0.98 – 2.52 0.0582 1.82 1.09 – 3.05 0.0230 
75 58 vs. 47 1.65 1.03 – 2.63 0.0373 1.81  1.08 – 3.04 0.0240 
80 24 vs. 81 1.09 0.66 – 1.89 0.743 1.13 0.63 – 2.14 0.692 
RDI, relative dose intensity; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval 
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Table 2: Patient background   
Variables 1c-RDI ≥ 60  
(n = 79) 
1c-RDI < 60 
(n = 26) 
p 
Sex  
 Female (ref. male) 
 
17 (21.5%) 
 
13 (50.0%) 
0.0053 
Age, years  
 ≥ 65 (ref. <65) 
 
36 (45.6%) 
 
15 (57.7%) 
0.283 
Body weight, kg 
< 50 (ref. ≥50) 
 
12 (15.2%) 
 
7 (26.9%) 
0.178 
Histology 
 Clear-cell carcinoma  
 Non-clear-cell carcinoma  
  Papillary renal cell carcinoma  
  Clear-cell carcinoma with spindle cell 
  Others/ unknown 
 
61 (77.2%) 
18 (22.8%) 
4 (5.06%) 
5 (6.33%) 
9 (11.4%) 
 
16 (61.5%) 
10 (38.5%) 
2 (7.69%) 
4 (15.4%) 
4 (15.4%) 
0.117 
Prior nephrectomy   
 With  
  Radical nephrectomy  
  Partial nephrectomy   
 Without 
 
72 (91.1%) 
68 (86.1%) 
4 (5.06%) 
7 (8.86%) 
 
22 (84.6%) 
22 (84.6%) 
0 
4 (15.4%) 
0.346 
MSKCC risk  
 Favorable  
 Intermediate  
 
13 (16.5%) 
55 (69.6%) 
 
3 (11.5%) 
19 (73.1%) 
0.830 
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 Poor 11 (13.9%) 4 (15.4%) 
Number of metastatic sites 
 Multiple (ref. single)  
 
41 (51.9%) 
 
12 (46.2%) 
0.611 
Initial dose, mg  
 50 (ref. ≤37.5) 
 
26 (32.9%) 
 
3 (11.5%) 
0.0345 
Treatment schedule  
 4-week-on/ 2-week-off (ref. 2-week-on/ 1-week-off) 
 
22 (27.9%) 
 
8 (30.8%) 
0.775 
Dose-limiting toxicity 
 With 
  Dose reduction 
  Treatment interruption  
 Without 
 
34 (43.0%) 
20 (25.3%) 
14 (17.7%) 
45 (57.0%) 
 
18 (69.2%) 
1 (3.85%) 
17 (65.4%) 
8 (30.8%) 
< 0.0001 
*Follow-up period, month 23.5 (11.0 – 39.3) 11.2 (4.43 – 20.6) 0.0037 
*Median (interquartile) 
MSKCC, Memorial Sloan Kettering Cancer Center 
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Table 3: Univariate and multivariate logistic regression analyses for 1c-RDI < 60% 
 Univariate Multivariate 
Variables  OR (95% CI) p OR (95% CI) p 
Sex  
 Female (ref. male) 
 
3.65 (1.43 – 9.31) 
0.0068  
3.11 (1.16 – 8.34) 
0.0240 
Age, years 
 ≥ 65 (ref. < 65) 
 
1.63 (0.67 – 3.99) 
0.286   
Body weight, kg  
 < 50 (ref. ≥ 50) 
 
2.06 (0.71 – 5.95) 
0.183   
Histology  
 Non-clear cell carcinoma (ref. clear-cell carcinoma) 
 
2.12 (0.82 – 5.47) 
0.121   
MSKCC risk 
 Favorable (ref. intermediate) 
 Poor (ref. intermediate) 
 
0.67 (0.17 – 2.60) 
1.06 (0.30 – 3.70) 
0.822 
0.561 
0.936 
  
Number of metastatic site 
 Multiple (ref. single) 
 
0.79 (0.33 – 1.93) 
0.612   
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Initial dose, mg 
 ≤ 37.5 (ref. 50) 
 
3.76 (1.03 – 13.7) 
0.0444  
3.58 (0.93 – 13.8) 
0.0632 
Treatment schedule  
 4-weeks-on/2-weeks-off (ref. 2-weeks-on/1week-off) 
 
1.15 (0.44 – 3.03) 
0.775   
Dose-limiting toxicity   
 With (ref. without) 
 
2.98 (1.16 – 7.66) 
0.0235  
3.09 (1.14 – 8.37) 
0.0266 
OR, odds ratio  
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Table 4: Individual adverse events inducing dose-limiting toxicities  
N = 52 
Grade 2 
Leukocytopenia    
 Thrombocytopenia      
 Hand-foot-syndrome  
 Nausea/vomiting/anorexia    
 Diarrhea 
 Fatigue    
 Fever 
 Hepatic injury 
 Interstitial lung disease 
 Hypertension  
 Mucotitis  
 Kidney injury  
 UTI 
 
3 (5.77%) 
16 (30.8%) 
2 (3.85%) 
4 (7.69%) 
1 (1.92%) 
3 (5.77%) 
4 (7.69%) 
1 (1.92%) 
1 (1.92%) 
1 (1.92%) 
1 (1.92%) 
1 (1.92%) 
1 (1.92%) 
Grade 3 or more  
 Leukocytopenia    
Thrombocytopenia      
 Hand-foot-syndrome  
 Fatigue    
 Hepatic injury 
 Pancreatic injury 
 
11 (21.2%) 
14 (26.9%) 
1 (1.92%) 
1 (1.92%) 
2 (3.85%) 
2 (3.85%) 
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 Hyperkalemia  
 Hepatic abscess 
 Gastrointestinal perforation 
3 (5.77%) 
1(1.92%) 
1(1.92%) 
Components of dose-liming toxicities 
 Dose reduction  
 Treatment interruption 
 
31 (59.6%) 
21 (40.4%) 
 
Supplementary Table 1. Univariate and multivariate analyses for progression-free survival
Univariate Multivariate
HR (95% CI) p HR (95% CI) p
Sex
 Female (ref. male) 1.78 (1.07 - 2.89) 0.0275 1.74 (1.02 - 2.90) 0.0415
Age
 ≧ 65 (ref. < 65) 0.94 (0.59 - 1.49) 0.781
Body Weight
 < 50 (≧ 50) 1.64 (0.89 - 2.84) 0.107
Histology
 Non-clear cell carcinoma (ref. clear-cell carcinoma) 2.76 (1.64 - 4.55) 0.0002 1.97 (1.15 - 3.31) 0.0135
MSKCC risk 0.0051 0.0154
 Favorable (ref. intermediate) 0.65 (0.30 - 1.26) 0.211 0.63 (0.28 - 1.26) 0.196
 Poor (ref. intermediate) 2.52 (1.33 - 4.48) 0.006 2.21 (1.16 - 3.96) 0.0175
Number of metastatic site
 Multiple (ref. single) 1.74 (1.09 - 2.80) 0.0198 1.77 (1.10 - 2.88) 0.0195
1c-RDI 
 < 60 (ref. ≧ 60) 2.31 (1.33 - 3.84) 0.0035 2.23 (1.27 - 3.79) 0.0063
Initial dose
≦ 35 (ref. 50) 1.21 (0.74 - 2.05) 0.461
Treatment schedule
 4-weeks-on/2-weeks-off (ref. 2-weeks-on/1week-off) 1.28 (0.76 - 2.08) 0.344
Dose-limiting toxicity
 With (ref.without) 1.35 (0.85 - 2.14) 0.202
Univariate Multivariate
HR (95% CI) p HR (95% CI) p
Sex
 Female (ref. male) 1.82 (1.05 - 3.07) 0.0344 1.72 (0.96 - 2.99) 0.0677
Age
 ≧ 65 (ref. < 65) 1.33 (0.80 - 2.24) 0.273
Body Weight
 < 50 (≧ 50) 1.82 (0.92 - 3.34) 0.0848
Histology 
 Non-clear cell carcinoma (ref. clear-cell carcinoma) 2.55 (1.42 - 4.43) 0.0022 2.07 (1.13 - 3.70) 0.0199
MSKCC risk 0.0023 0.0026
 Favorable (ref. intermediate) 0.59 (0.24 - 1.25) 0.179 0.55 (0.22 - 1.19) 0.137
 Poor (ref. intermediate) 3.03 (1.50 - 5.73) 0.003 2.93 (1.44 - 5.61) 0.0042
Number of metastatic site
 Multiple (ref. single) 2.24 (1.33 - 3.87) 0.0025 2.65 (1.53 - 4.68) 0.0004
1c-RDI 
 < 60 (ref. ≥ 60) 2.55 (1.45 - 4.36) 0.0015 2.64 (1.45 - 4.68) 0.0018
Initial dose
≦ 35 (ref. 50) 1.17 (0.67 - 2.14) 0.595
Treatment schedule
 4-weeks-on/2-weeks-off (ref. 2-weeks-on/1week-off) 1.27 (0.72 - 2.16) 0.406
Dose-limiting toxicity
 With (ref.without) 1.42 (0.85 - 2.38) 0.179
Supplementary Table 2. Univariate and multivariate analyses for overall survival
